| Record Information |
|---|
| Version |
3.5 |
| Creation Date |
2006-10-16 07:00:12 -0600 |
| Update Date |
2013-02-08 17:13:46 -0700 |
| HMDB ID |
HMDB05012 |
| Secondary Accession Numbers |
None |
| Metabolite Identification |
|---|
| Common Name |
Olanzapine |
| Description |
Olanzapine was the third atypical antipsychotic to gain approval by the Food and Drug Administration (FDA) and has become one of the most commonly used atypical antipsychotics. Olanzapine has been approved by the FDA for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder and psychotic depression. It has also been established in treating depression off-label because of its mood-stabilizing properties and its ability to increase the efficacy of antidepressants. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company. It is available as a pill that comes in the strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg and as as Zydis orally disintegrating tablets in the strengths of 5 mg, 10 mg, 15 mg, and 20 mg. It is also available as a rapid-acting intramuscular injection for short term acute use. Olanzapine (oh-LAN-za-peen, sold as Zyprexa, Zydis, or in combination with fluoxetine, as Symbyax) was the third atypical antipsychotic to gain approval by the Food and Drug Administration (FDA) and has become one of the most commonly used atypical antipsychotics. Olanzapine has been approved by the FDA for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder and psychotic depression. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- Lanzac
- Olanzapine
- Zyprexa
- Zyprexa Intramuscular
- Zyprexa Zydis
|
| Chemical Formula |
C17H20N4S |
| Average Molecular Weight |
312.432 |
| Monoisotopic Molecular Weight |
312.14086735 |
| IUPAC Name |
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene |
| Traditional IUPAC Name |
5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene |
| CAS Registry Number |
132539-06-1 |
| SMILES |
CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 |
| InChI Identifier |
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3 |
| InChI Key |
KVWDHTXUZHCGIO-UHFFFAOYSA-N |
| Chemical Taxonomy |
|---|
| Kingdom |
Organic Compounds |
| Super Class |
Aromatic Heteropolycyclic Compounds |
| Class |
Benzodiazepines |
| Sub Class |
N/A |
| Other Descriptors |
- N-arylpiperazine(ChEBI)
- N-methylpiperazine(ChEBI)
- benzodiazepine(ChEBI)
|
| Substituents |
- Carboxylic Acid Amidine
- Para Diazepine
- Piperazine
- Tertiary Aliphatic Amine (Trialkylamine)
- Thiophene
|
| Direct Parent |
Benzodiazepines |
| Ontology |
|---|
| Status |
Expected and Not Quantified |
| Origin |
|
| Biofunction |
Not Available |
| Application |
Not Available |
| Cellular locations |
Not Available |
| Physical Properties |
|---|
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
Not Available |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
Not Available |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|---|
|
Not Available
|
| Biological Properties |
|---|
| Cellular Locations |
Not Available
|
| Biofluid Locations |
Not Available
|
| Tissue Location |
|
| Pathways |
Not Available
|
| Normal Concentrations |
|---|
|
Not Available |
| Abnormal Concentrations |
|---|
|
Not Available |
| Associated Disorders and Diseases |
|---|
| Disease References |
None |
| Associated OMIM IDs |
None |
| External Links |
|---|
| DrugBank ID |
Not Available |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB023585 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
10442212  |
| KEGG Compound ID |
C07322 |
| BioCyc ID |
Not Available |
| BiGG ID |
Not Available |
| Wikipedia Link |
Olanzapine |
| NuGOwiki Link |
HMDB05012 |
| Metagene Link |
HMDB05012 |
| METLIN ID |
Not Available |
| PubChem Compound |
Not Available |
| PDB ID |
Not Available |
| ChEBI ID |
7735 |
| References |
|---|
| Synthesis Reference |
Patel, Hiren V.; Ray, Anup K.; Patel, Pramod B.; Patel, Mahendra R. Process of preparation of olanzapine form I. PCT Int. Appl. (2003), 16 pp. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Cerdan LF, Guevara MA, Sanz A, Amezcua C, Ramos-Loyo J: Brain electrical activity changes in treatment refractory schizophrenics after olanzapine treatment. Int J Psychophysiol. 2005 Jun;56(3):237-47.
Pubmed: 15866327
- Horak EL, Jenkins AJ: Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication. J Forensic Sci. 2005 May;50(3):679-81.
Pubmed: 15932107
- Yamada K, Isotani T, Irisawa S, Yoshimura M, Tajika A, Yagyu T, Saito A, Kinoshita T: EEG Global Field Power spectrum changes after a single dose of atypical antipsychotics in healthy volunteers. Brain Topogr. 2004 Summer;16(4):281-5.
Pubmed: 15379228
- Mortimer A, Martin S, Loo H, Peuskens J: A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004 Mar;19(2):63-9.
Pubmed: 15076013
- Merrick TC, Felo JA, Jenkins AJ: Tissue distribution of olanzapine in a postmortem case. Am J Forensic Med Pathol. 2001 Sep;22(3):270-4.
Pubmed: 11563738
|
